Donor-specific antibody against denatured HLA-A1: Clinically nonsignificant?

Human Immunology

Volumn 72, Issue 6, 2011, Pages 492-498

  Pereira, Shalini ^a   Perkins, Susan ^b   Lee, Jar How ^c   Shumway, Wayne ^d   LeFor, William ^d   Lopez Cepero, Mayra ^d   Wong, Cynthia ^e   Connolly, Amy ^e   Tan, Jane C ^f   Grumet, F Carl ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c One Lambda Inc   (United States)

^d LifeLink Foundation   (United States)

^e LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibody; Antigen; Denatured; HLA; Renal transplant

Indexed keywords

CREATININE; HLA A1 ANTIGEN;

ACUTE GRAFT REJECTION; ARTICLE; CADAVER KIDNEY; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PROTEIN DENATURATION; RETROSPECTIVE STUDY; TRANSPLANTATION;

BLOOD GROUPING AND CROSSMATCHING; CELL SEPARATION; CREATININE; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HUMANS; IMMUNITY, HUMORAL; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROTEIN DENATURATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 79955778087     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.02.012     Document Type: Article

References (12)

1. Patel R., Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969, 280:735-739.
2. Bray R.A., Nickerson P.W., Kerman R.H., Gebel H.M. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004, 29:41-54.
3. Gebel H.M., Bray R.A., Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003, 3:1488-1500.
4. Gebel H.M., Bray R.A., Ruth J.A., Zibari G.B., McDonald J.C., Kahan B.D., et al. Flow PRA to detect clinically relevant HLA antibodies. Transplant Proc 2001, 33:477.
5. Gebel H.M., Harris S.B., Zibari G., Bray R.A. Conundrums with FlowPRA beads. Clin Transpl 2002, 16(Suppl 7):24-29.
6. Pei R., Bray R., Lopez-Cepero M., Lee J.-H. Detection of antibodies against beta2-microglobulin free HLA heavy chains using FlowPRA Beads. Visuals of the Clinical Histocompatibility Workshop 2000, 9. Montego Bay, Jamaica. P.I. Terasaki (Ed.).
7. Sugawara S., Abo T., Kumagai K. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. J Immunol Methods 1987, 100:83-90.
8. Polakova K., Karpatova M., Russ G. Dissociation of beta 2-microglobulin is responsible for selective reduction of HLA class I antigenicity following acid treatment of cells. Mol Immunol 1993, 30:1223-1230.
9. Shumway W.A., Wright L., LeFor W.M. HLA antibody in solid phase but not cellular assays: Linear vs conformational epitopes. Hum Immunol 2005, 66(Suppl 1):41.
10. Lopez-Cepero M. Detection of an HLA antibody against HLA class I by Flow PRA Beads and LAT assays but not by cell dependent assays such as CDC-AHG and flow cell pools and its possible post-transplant implication. Visuals of the Clinical Histocompatibility Workshop 2000, 11. Transplant Immunology Laboratory, Terasaki, PI.
11. Zijlstra M., Bix M., Simister N.E., Loring J.M., Raulet D.H., Jaenisch R. Beta2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature 1990, 344:742-746.
12. Bix M., Raulet D. Functionally conformed free class I heavy chains exist on the surface of beta 2-microglobulin negative cells. J Exp Med 1992, 176:829-834.